---
deliverable_id: folio-correspondence-ingest-v1-3-0
phase: B.1
role: alignment
family: codex
status: completed
evidence_labels_used:
  - direct-run
---
# B.1 Alignment Review: folio-correspondence-ingest-v1-3-0

## Verdict
approve

## Review Scope
Reviewed only the requested Phase A inputs for this slice:

- `docs/validation/strict_p3_rerun_2026_05_12/pre_a_triage.md`
- `docs/validation/strict_p3_rerun_2026_05_12/folio-correspondence-ingest-v1-3-0_phase_a_spec.md`
- `frameworks/manifests/folio-correspondence-ingest-v1-3-0.yaml`

This review assesses whether the Phase A spec and manifest are adequate to drive `folio-correspondence-ingest-v1-3-0` through strict-P3 Phase B.1 without relying on stale lifecycle evidence.

## Findings
No blockers found.

The Phase A spec correctly anchors scope to issues `#61` and `#64` via `docs/validation/strict_p3_rerun_2026_05_12/pre_a_triage.md`, and it explicitly states that prior `folio_*_v1_*` artifacts are not lifecycle evidence. Its acceptance criteria cover the required user-facing contract: `folio ingest-email <path.eml>`, `folio ingest <path.eml> --type email_thread`, parsing of email structure and attachment metadata, `message_ids`, Message-ID overlap continuation/versioning, and the `--as-new-entry` override.

The manifest aligns with that scope. Its summary, `pre_a.artifact_path`, allowed implementation paths, test paths, family assignments, strict lifecycle receipt inventory path, and review-board artifact patterns all point at the strict-P3 rerun area for this deliverable. The B.1 model assignment maps `codex` to `alignment`, matching this artifact. The manifest does not enumerate or depend on older closeout artifacts as review evidence, and its lifecycle settings require fresh receipt-gated review and verification flow.

## Adequacy
The spec is concise, but it is adequate because it delegates detailed behavior to the regenerated triage artifact and captures the slice's implementation and validation contract. The manifest is also adequate for role alignment: it fences writes to the expected code, test, manifest, validation, and deliverable-specific review-board paths; forbids local secret files and API-key strings; and defines focused tests plus strict D.6 lifecycle checks. I do not see stale evidence reuse risk in the Phase A spec or manifest that would block this slice from proceeding.
